Hint mode is switched on Switch off
For swift navigation between sections

Omeros Corp
LEI 549300CJWLXX2MXVVV71

PDF download

Choose all Reset all
Download Cancel
Organization name
Omeros Corporation
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
142 mln USD

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Awards

News

13/05/2026 Omeros Corporation Reports First Quarter 2026 Financial Results
31/03/2026 Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
26/03/2026 Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
07/01/2026 Omeros Corp: Of Form 8k, This Filing Is Being Made To Report That At December 31, 2025,we Had Approximately $171.5 Million Of Cash And Shortterm Investments Available For Operations. This Figure Is Preliminary And Unaudited. It Is Subject To Completion Of The Company’s Customary Financial Closing Procedures And Adjustments
25/11/2025 Omeros Corp: Below. Substantially Concurrent With The Closing Of Such Transaction, The Company Utilized A Portion Of The $240.0 Million Upfront Payment That It Received To Repay All Outstanding Obligations Under The Credit And Guarantee Agreement, Dated June 3, 2024 (the “credit Agreement”), Among The Company, The Various Lenders Party Thereto, And Wilmington Savings Fund Society, Fsb, As Administrative Agent And Collateral Agent. The Retirement Included Prepayment Of The $67.1 Million Outstanding Term Loan Under The Credit Agreement, A $3.4million Mandatory Prepayment Premium, $2.0 Million Of Incurredinterest, And Approximately $0.1million Of Transaction Related Expenses. Repayment Of The Company’s Obligations Under The Credit Agreement Resulted In The Simultaneous Release In Full Of All Liens And Covenants Thereunder, Including The Covenant Requiring The Company To Maintain At All Times A Minimum Of $25.0 Million Of Unrestricted Cash, Cash Equivalents And Shortterm Investments, Releasing Such $25.0 Million Into The Company's Working Capital Available For Use. Upon The Occurrence Of Such Events, The Credit Agreement Was Terminated
All organization news

Documentation

IFRS/US GAAP reports

2025
I q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300CJWLXX2MXVVV71
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001285819
  • EIN
    91-1663741
Registration is required to get access.